Continuous drop in combined cancer death rate from 1991 to 2015, resulting in 2,378,600 fewer death.
Higher mortality for heart transplant patients with de novo solid malignancy than those without malignancy.
Durable survival, response rates rarely recognized as significant by current oncology value frameworks.
Most patients with cancer, autoimmune disease have improvement in events without discontinuing therapy.
Across cancers, higher costs tied to higher rates of oral prescription abandonment, delayed initiation.
Certain chemotherapies might shorten telomeres and alter microRNA.
Patients with end-stage renal disease (ESRD) have a 6-fold and 4.4-fold increased risk of kidney cancer and urothelial cancers, respectively, than individuals without ESRD.
ERK1/2 kinase inhibitor, ulixertinib, was used to treat cancer patients with MAPK mutant solid tumors.
Male patients with mCRPC and seizure risk factors did not have increased seizure incidents when taking Enzalutamide.
Cancer survival was greatly skewed toward patients with Medicare or private insurance.
About 45.1% of cancer deaths and 42% of all incident cancers are linked to modifiable risk factors.
Comorbidity may be higher in American Indians and Native Alaskans than in non-Hispanic white cancer patients.
The combined effects of high BMI and diabetes resulted in 5.6% of all incident cancers in 2012.
6 weeks Swedish massage therapy significantly decreased cancer-related fatigue in female breast cancer survivors.
About one-fourth of older cancer patients were previously diagnosed.
Coffee consumption was affiliated with more positives than negatives across a wide range of health outcomes.
For this population-based cohort study, researchers analyzed the health outcomes of 1,256,725 patients and separated them into warfarin- and non-warfarin-using subgroups.
General practitioners less likely to support smoking cessation in patients with cancer than with CHD
Direct oral anticoagulants not linked to increased risk of major bleeding, death in venous thromboembolism
Legalization increases likelihood of use; most want information about the drug from their doctors
The researchers found that 2.9% of the 347 patients treated with anti-PD-1 monoclonal antibodies developed subacute onset of neurological complications.
Mvasi, which is approved to treat colorectal, lung, brain, kidney, and cervical cancer, was found to be biosimilar to the drug Avastin.
AACR reports that the US cancer death rate has decreased 25% from 1991 to 2014, resulting in 2.1 million fewer cancer-related deaths.
Knowledge of these additional mutations can help guide therapeutic and preventive interventions.
The findings showed that only 29.1% of the skin cancers started in moles patients already had.
After 11 pounds gained, the risk of diabetes went up 31%, hypertension 14%, and cardiovascular disease 8%.
The increased risk for obesity-related cancer was seen among women who were normal weight at enrollment.
The researchers found that after VTE diagnosis, the 12-month prevalence of cancer was 5.2%.
There were no significant changes in insurer approval rates or referral wait times for patients covered by Medicare or Medicaid.
Evidence suggests that using alternative medicine in place of proven cancer therapies results in worse survival.
Renal and Urology News Articles
- CROWNWeb Reporting Gets Up to Speed With Implementation of Dashboard
- Prostate Cancer Gene Testing Guidelines Issued
- Radical Nephrectomy Linked With Worse Kidney Function, Survival
- Acute Kidney Injury Increases Risk for Hypoglycemia in Diabetes Pts
- USPSTF Questions Nontraditional CVD Risk Factors for Assessment
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)